These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 12172461)

  • 21. Fondaparinux: basic properties and efficacy and safety in venous thromboembolism prophylaxis.
    Bauer KA
    Am J Orthop (Belle Mead NJ); 2002 Nov; 31(11 Suppl):4-10. PubMed ID: 12463577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis.
    Sobieraj DM; Coleman CI; Tongbram V; Chen W; Colby J; Lee S; Kluger J; Makanji S; Ashaye A; White CM
    Pharmacotherapy; 2012 Sep; 32(9):799-808. PubMed ID: 22744711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [From heparin to synthetic antithrombotic drugs].
    Palareti G; Cosmi B
    Minerva Anestesiol; 2001 Sep; 67(9 Suppl 1):76-81. PubMed ID: 11778099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study.
    Eriksson BI; Lassen MR;
    Arch Intern Med; 2003 Jun; 163(11):1337-42. PubMed ID: 12796070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fondaparinux (Arixtra): a new anticoagulant.
    Giangrande PL
    Int J Clin Pract; 2002 Oct; 56(8):615-7. PubMed ID: 12425373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deep venous thrombosis and pulmonary embolism. Part 1. Initial treatment: usually a low-molecular-weight heparin.
    Prescrire Int; 2013 Apr; 22(137):99-101, 103-4. PubMed ID: 23662321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty.
    Freedman KB; Brookenthal KR; Fitzgerald RH; Williams S; Lonner JH
    J Bone Joint Surg Am; 2000 Jul; 82-A(7):929-38. PubMed ID: 10901307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pentasaccharide Org31540/SR90107A clinical trials update: lessons for practice.
    Turpie AG
    Am Heart J; 2001 Aug; 142(2 Suppl):S9-15. PubMed ID: 11479485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison.
    Lassen MR; Bauer KA; Eriksson BI; Turpie AG;
    Lancet; 2002 May; 359(9319):1715-20. PubMed ID: 12049858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.
    Eriksson BI; Bauer KA; Lassen MR; Turpie AG;
    N Engl J Med; 2001 Nov; 345(18):1298-304. PubMed ID: 11794148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention of deep vein thrombosis with low molecular-weight heparin in patients undergoing total hip replacement. A randomized trial. The German Hip Arthroplasty Trial (GHAT) Group.
    Arch Orthop Trauma Surg; 1992; 111(2):110-20. PubMed ID: 1314065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and experimental experience with factor Xa inhibitors.
    Viles-Gonzalez JF; Gaztanaga J; Zafar UM; Fuster V; Badimon JJ
    Am J Cardiovasc Drugs; 2004; 4(6):379-84. PubMed ID: 15554723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery.
    Agnelli G; Bergqvist D; Cohen AT; Gallus AS; Gent M;
    Br J Surg; 2005 Oct; 92(10):1212-20. PubMed ID: 16175516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa.
    Petitou M; Duchaussoy P; Herbert JM; Duc G; El Hajji M; Branellec JF; Donat F; Necciari J; Cariou R; Bouthier J; Garrigou E
    Semin Thromb Hemost; 2002 Aug; 28(4):393-402. PubMed ID: 12244487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prevention of venous thromboembolism after major orthopedic surgery: update and contribution of a specific synthetic inhibitor of factor Xa].
    Samama MM
    Rev Chir Orthop Reparatrice Appar Mot; 2003 Dec; 89(8):712-24. PubMed ID: 14726838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-molecular-weight heparin versus compression stockings for thromboprophylaxis after knee arthroscopy: a randomized trial.
    Camporese G; Bernardi E; Prandoni P; Noventa F; Verlato F; Simioni P; Ntita K; Salmistraro G; Frangos C; Rossi F; Cordova R; Franz F; Zucchetta P; Kontothanassis D; Andreozzi GM;
    Ann Intern Med; 2008 Jul; 149(2):73-82. PubMed ID: 18626046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reviparin: a review of its efficacy in the prevention and treatment of venous thromboembolism.
    Wellington K; McClellan K; Jarvis B
    Drugs; 2001; 61(8):1185-209. PubMed ID: 11465877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial.
    Beyer-Westendorf J; Schellong SM; Gerlach H; Rabe E; Weitz JI; Jersemann K; Sahin K; Bauersachs R;
    Lancet Haematol; 2017 Mar; 4(3):e105-e113. PubMed ID: 28219692
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.